Introduction of New Therapeutic Substances

Why This Topic Matters

These updates affect how new therapies and administration routes are represented in ICD-10-PCS, which can influence inpatient coding accuracy, data reporting, and reimbursement workflows. The article helps readers recognize which new therapeutic products and treatment categories are included so they can assess whether the full guidance is relevant to their cases.

Article Sections

1. Overview of new substance values in Table XW0

   Introduces the new substance values added to an ICD-10-PCS table and notes the associated technology value. This section sets the scope for the therapy categories covered in the article.

2. Spesolimab Monoclonal Antibody

   Covers one of the newly discussed therapeutic substances and the related administration context. Background is provided on the therapy’s general clinical use and the type of coding update involved.

3. Daratumumab and Hyaluronidase-fihj

   Describes another new therapeutic substance and its general treatment context. The section provides clinical background relevant to the associated coding update.

4. Maribavir Anti-infective

   Addresses a new anti-infective therapy and the administration settings referenced in the article. The section explains the broader clinical setting for the code changes.

5. Teclistamab Antineoplastic

   Summarizes a newly discussed immunotherapy used in hematologic oncology. The section links the therapy to the broader administration coding update.

6. Mosunetuzumab Antineoplastic

   Covers a bispecific antibody therapy and its role in cancer treatment. The section focuses on the associated inpatient coding topic and clinical background.

7. Afamitresgene Autoleucel Immunotherapy

   Discusses an autologous cell therapy and the general treatment setting in which it is used. The section provides context for the related administration code additions.

8. Tabelecleucel Immunotherapy

   Reviews a cell-based immunotherapy and the clinical situation described in the article. The section highlights the broader reason new administration codes were created.

9. Treosulfan

   Covers a conditioning-related therapeutic substance and its transplant-related context. The section explains why new administration coding was introduced.

10. Inebilizumab-cdon

    Discusses a newly referenced biologic therapy and the condition it is associated with. The section places the update within a broader autoimmune disease context.

11. Engineered Allogeneic Thymus Tissue

    Describes a tissue-based therapy and the patient population mentioned in the article. The section provides background on the procedural setting referenced for coding.

12. Broad Consortium Microbiota-Based Live Biotherapeutic Suspension

    Covers a microbiota-based therapeutic product and the general setting for its administration. The section provides context for the newly created code discussed in the article.